European Patent Organisation

Bound2B Files Patent Infringement Case Against the Ardagh Group, Xolution and Weider in Germany

Retrieved on: 
Tuesday, June 2, 2020

Bound2B - owner of EP' 930, covering devices for closing beverage and corresponding food containers, in particular resealable cans believes that resealable cans equipped with Xolution's XO System infringe its patent EP' 930.

Key Points: 
  • Bound2B - owner of EP' 930, covering devices for closing beverage and corresponding food containers, in particular resealable cans believes that resealable cans equipped with Xolution's XO System infringe its patent EP' 930.
  • Such cans have been distributed by Weider in Germany.
  • The validity of EP' 930 was confirmed in opposition proceedings before the European Patent Office (EPO) in 2011.
  • This filing follows legal proceedings filed in 2018 by Bound2B against a further company of the Ardagh Group in the Netherlands with regard to an alleged breach of contract by Ardagh.

OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System

Retrieved on: 
Wednesday, May 27, 2020

The European Patent Office intends to grant a patent covering OncoSec's gene therapy and electroporation for the treatment of malignancies.

Key Points: 
  • The European Patent Office intends to grant a patent covering OncoSec's gene therapy and electroporation for the treatment of malignancies.
  • Additionally, the European Patent Office also intends to grant a second patent protecting OncoSec's next-generation electroporation gene delivery system focused on the treatment of internal or visceral lesions.
  • The Canadian Intellectual Property Office intends to grant a patent protecting OncoSec's electroporation method for treating microscopic tumors.
  • "OncoSec continues to prioritize the expansion of its intellectual property portfolio across multiple facets of its technology," said Keir Loiacono, Vice President, Corporate Development at OncoSec Medical Incorporated.

Grant of European Patent for ColdZyme

Retrieved on: 
Tuesday, May 19, 2020

STOCKHOLM, May 19, 2020 /PRNewswire/ -- The European Patent Office has granted Enzymatica's patent for the key cod enzyme component of Enzymatica's cold spray ColdZyme for the European market.

Key Points: 
  • STOCKHOLM, May 19, 2020 /PRNewswire/ -- The European Patent Office has granted Enzymatica's patent for the key cod enzyme component of Enzymatica's cold spray ColdZyme for the European market.
  • Enzymatica announced on February 3 that the European Patent Office intended to grant a patent for the cod enzyme, which is one of the key components of ColdZyme.
  • Enzymatica has developed an improved cod enzyme formulation for ColdZyme, for which new patent applications were globally filed in 2015 (European patent application number 16745663.1).
  • The latest European patent is derived from this new patent family.

CaseLines Announces Patent Application for Differential Redaction By Sub-Bundle

Retrieved on: 
Wednesday, May 13, 2020

LONDON and WASHINGTON, May 13, 2020 /PRNewswire/ --CaseLines today announced that it has filed a patent application for a unique tool that enables differential redaction by sub-bundle for the legal industry.

Key Points: 
  • LONDON and WASHINGTON, May 13, 2020 /PRNewswire/ --CaseLines today announced that it has filed a patent application for a unique tool that enables differential redaction by sub-bundle for the legal industry.
  • The differential redaction tool saves CaseLines users an immense amount of time when preparing material for sharing as a case progresses.
  • This patent application shows that CaseLines is unique in being able to deliver redaction in this flexible, productive and progressive way," explains Paul Sachs, CTO and founder of CaseLines.
  • This patent application announcement follows a previous announcement of a patent application for the use of blockchain within the CaseLines platform, to track the digital journey of legal documentation.

CaseLines Announces Patent Application for Differential Redaction By Sub-Bundle

Retrieved on: 
Wednesday, May 13, 2020

LONDON and WASHINGTON, May 13, 2020 /PRNewswire/ --CaseLines today announced that it has filed a patent application for a unique tool that enables differential redaction by sub-bundle for the legal industry.

Key Points: 
  • LONDON and WASHINGTON, May 13, 2020 /PRNewswire/ --CaseLines today announced that it has filed a patent application for a unique tool that enables differential redaction by sub-bundle for the legal industry.
  • The differential redaction tool saves CaseLines users an immense amount of time when preparing material for sharing as a case progresses.
  • This patent application shows that CaseLines is unique in being able to deliver redaction in this flexible, productive and progressive way," explains Paul Sachs, CTO and founder of CaseLines.
  • This patent application announcement follows a previous announcement of a patent application for the use of blockchain within the CaseLines platform, to track the digital journey of legal documentation.

Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due to COVID-19

Retrieved on: 
Tuesday, May 12, 2020

On January 29, 2018, the Opposition Division of the EPO concluded the oral proceedings concerning the 355 Patent (the Opposition Proceeding).

Key Points: 
  • On January 29, 2018, the Opposition Division of the EPO concluded the oral proceedings concerning the 355 Patent (the Opposition Proceeding).
  • On March 22, 2018, the Opposition Division issued its detailed reasons for the decision.
  • On May 7, 2018, the Company appealed the Opposition Divisions decision to the TBA and filed its detailed grounds of appeal on August 1, 2018.
  • Management expects the TBA to issue a ruling on the same day as the hearing, with a fully reasoned decision approximately two months following the hearing.

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

Retrieved on: 
Tuesday, May 12, 2020

The patent application, entitled "Compositions and Methods for Use of Cannabinoids for Neuroprotection" represents an important step in protecting the Company's intellectual property and commercial opportunities.

Key Points: 
  • The patent application, entitled "Compositions and Methods for Use of Cannabinoids for Neuroprotection" represents an important step in protecting the Company's intellectual property and commercial opportunities.
  • Currently approved glaucoma therapies are typically intended to decrease intraocular pressure, which may lead to an indirect effect of reducing neuron damage in the eye.
  • The PCT is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states.
  • There are 151 member countries within the PCT, enabling near-global patent coverage through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, as well as many others.

JTI Ranks Among Top 100 for European Patent Applications

Retrieved on: 
Thursday, March 19, 2020

GENEVA, March 19, 2020 /PRNewswire/ -- JTI was one of the top 100 applicants at the European Patent Office (EPO), according to the EPO's Patent Index 2019.

Key Points: 
  • GENEVA, March 19, 2020 /PRNewswire/ -- JTI was one of the top 100 applicants at the European Patent Office (EPO), according to the EPO's Patent Index 2019.
  • Globally, the JT Group has a portfolio of 4200 granted patents and 2800 pending patent applications, with 355 priority applications filed by the Group in 2019, covering the development of its diverse product families.
  • JTI is also a major player in the international vaping market with its brand, Logic and tobacco vapor brand, Ploom.
  • Headquartered in Geneva, Switzerland, JTI employs approximately 45,000 people and was awarded Global Top Employer for the sixth consecutive year.

US Patent Practice | London, United Kingdom - June 11-12, 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 17, 2020

The "US Patent Practice" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Patent Practice" conference has been added to ResearchAndMarkets.com's offering.
  • This highly interactive seminar will give you a comprehensive understanding of the US patent system and enable you to work more effectively with your US counterparts.
  • It will highlight the important differences between US and European patent practice and provide you with the opportunity for in-depth discussions about prosecution practice and procedure throughout the two days.
  • Offering a wide-ranging and detailed understanding, this seminar covers what every European patent practitioner should know about US patent practice.

AI Drives Patent Applications from U.S. Companies at the European Patent Office to New Record High

Retrieved on: 
Thursday, March 12, 2020

MUNICH, Germany, March 12, 2020 /PRNewswire-PRWeb/ -- The European Patent Office (EPO) today announced that U.S. companies and inventors filed over 46,200 European patent applications in 2019, 5.5% more than in the previous year, according to its Patent Index 2019 (Graph: Growth of patent applications at the EPO from the U.S. ).

Key Points: 
  • MUNICH, Germany, March 12, 2020 /PRNewswire-PRWeb/ -- The European Patent Office (EPO) today announced that U.S. companies and inventors filed over 46,200 European patent applications in 2019, 5.5% more than in the previous year, according to its Patent Index 2019 (Graph: Growth of patent applications at the EPO from the U.S. ).
  • With a share of 25% of all patent applications, the U.S. remained the most active country of origin for patent applications filed with the EPO (Graph: Origin of applications ).
  • Overall, the European Patent Office received 181,000 patent applications in 2019, an increase of 4% compared to 2018 (Graph: Growth of European patent applications ).
  • With nearly 7,000 staff, the European Patent Office (EPO) is one of the largest public service institutions in Europe.